Merck & Co.’s Keytruda/Inlyta Combo Invades Kidney Cancer Territory
Executive Summary
Merck & Co.’s IO powerhouse Keytruda has trumped Bavencio’s recent Inlyta combo PFS win in kidney cancer, with a OS and PFS combo hit of its own. But the field is getting increasingly crowded.
You may also be interested in...
Keytruda Is King, But Merck Faces Questions About Business Development
Keytruda continues to break records on the strength of its efficacy in lung cancer, and shows no signs of slowing down. But analysts were intrigued by repeated mentions of business development during Merck’s third quarter earnings call.
Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity
Bristol says its checkpoint immunotherapies can hold the lead in renal cell carcinoma, despite increasing competition.
Cash-Rich Ipsen Opens Up Checkbook For 2019
2019 looks set to be a transformative year for Ipsen, with a pivotal clinical trial readout expected for combination Cabometyx in frontline kidney and liver cancer, and a series of deals promised by the company to investors looking for reassurance over long-term growth. CEO David Meek spoke to Scrip.